44th Annual J.P. Morgan Healthcare Conference Andrew Hider President & Chief Executive Officer January 12, 2026 1 Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results (including the company's net leverage target and estimated timing considerations) and operational, business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause a ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious malfunctions and risks to patient safety [5] - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5] - The firm claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to serious safety issues related to its Novum IQ Large Volume Pump, which has been linked to patient injuries and deaths, leading to a significant drop in stock price [1][4][5]. Group 1: Incident Overview - On April 7, 2025, a Missouri news outlet reported safety issues with Baxter's Novum LVP, claiming it was unsafe for patient treatment based on a whistleblower's information [2]. - Baxter issued warning letters on April 24 and July 14, 2025, regarding underinfusion and overinfusion risks, revealing 79 reports of serious injuries and two patient deaths associated with the device [3]. - The FDA classified the issues with Novum LVP as a Class I recall, indicating a severe risk of injury or death [3]. Group 2: Stock Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price fell by $6.24, or 22.4%, closing at $21.61 per share [4]. Group 3: Lawsuit Details - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of the Novum LVP, failing to disclose systemic defects and the risks associated with the device [5]. - It is claimed that Baxter was aware of multiple malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Baxter International Inc. has announced early tender results for cash tender offers for its 2026 and 2027 Notes, with a maximum purchase price of up to $600 million for the 2027 Notes [1][2]. Group 1: Tender Offer Details - The tender offers include the purchase of all 2.600% senior unsecured notes due 2026 and a portion of the 1.915% senior unsecured notes due 2027 [2]. - The total principal amount of the 2026 Notes outstanding is $750 million, with $420.589 million tendered by the early tender date [4]. - For the 2027 Notes, the total outstanding is $1.45 billion, with $1.08866 billion tendered [4]. Group 2: Early Tender Date and Settlement - The early tender date was set for December 3, 2025, at 5:00 p.m. New York City time, after which withdrawal rights expired [3]. - The company plans to make payments for the validly tendered notes on December 8, 2025, which is the early settlement date [4]. Group 3: Total Consideration and Pricing - The total consideration for the notes accepted for purchase will include an early tender payment of $30.00 per $1,000 principal amount and will be determined based on the applicable fixed spread and yield of U.S. Treasury reference securities [5]. - The total consideration will be announced on December 4, 2025, at 10:00 a.m. New York City time [5]. Group 4: Pro Rata Acceptance - Due to the expected exceedance of the maximum tender cap for the 2027 Notes, any tendered 2027 Notes will be accepted on a pro rata basis [6]. - The company does not anticipate accepting any 2027 Notes tendered after the early tender date [6]. Group 5: Conditions and Management - The tender offers are subject to certain conditions, including the financing condition specified in the Offer to Purchase [8]. - Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC are the dealer managers for the tender offers [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 15, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious malfunctions and risks to patient safety [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and sales halts [5]. - The firm claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff is required to file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which resulted in injuries and deaths [5] - Baxter's inadequate responses to these defects and the potential halting of new sales of the pumps contributed to misleading statements regarding the product's safety and sales prospects [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [6]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP, and that their remedial measures were inadequate [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5]. - The firm has been recognized for its performance in the field, being ranked highly for the number of securities class action settlements [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions and potential injuries or deaths [6]. - The lawsuit claims that Baxter's attempts to address these defects were inadequate, and as a result, there was a heightened risk of customers removing the Novum LVPs from service and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [5]. - The firm has been recognized for its achievements in the field, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [5].